Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) said on Friday that new analyses from the multinational MILOS study demonstrate the real-world impact of bempedoic acid, used alone or in combination with ezetimibe, in managing dyslipidemia and cardiovascular risk.
Among 960 at-risk patients, one year of bempedoic acid add-on therapy was estimated to translate into a 17.1% relative and 4.8% absolute reduction in predicted 10-year risk of a major cardiovascular event. Real-world data also showed mean reductions in low-density lipoprotein cholesterol (LDL-C) of at least 24.9% after one year, regardless of diabetes status, pre-diabetes, normoglycemia or sex.
The treatment delivered a 31% relative LDL-C reduction in women and 25% in men, and increased the proportion of patients reaching LDL-C goals within one year.
These findings, presented at the European Society of Cardiology Congress 2026 in Munich, reinforce the clinical value of bempedoic acid-based therapies in routine practice.
MILOS is an ongoing multinational European observational study evaluating the real-world use of bempedoic acid and the fixed-dose combination of bempedoic acid and ezetimibe in adults with primary hypercholesterolaemia or mixed dyslipidemia.
Oracle partners AstraZeneca for AI-enabled healthcare innovation
Medtronic confirms separation of MiniMed
Philips-led EXIT-CVD consortium launches cardiovascular clinical studies across Europe
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Otsuka ICU Medical recalls 0.9% Sodium Chloride Injection
US FDA grants orphan drug designation for Lundbeck's asedebart
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
Lilly to acquire Merida Biosciences in USD2.875bn deal
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Revier Therapeutics closes EUR6m seed financing and launches operations
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product